Andros Pharmaceuticals Co., Ltd.

As of June 30, 2026, Andros Pharmaceuticals Co., Ltd. carries a market capitalization of 1.70B, placing it among publicly traded companies globally. Its enterprise value stands at 1.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Andros Pharmaceuticals Co., Ltd. has 55.27M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Andros Pharmaceuticals Co., Ltd. maintains a current ratio of 12.91, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Andros Pharmaceuticals Co., Ltd.'s stock has gained approximately 70.21% over the past 52 weeks. The 50-day moving average sits at 33.78, while the 200-day moving average is 30.20.

As of June 30, 2026, Andros Pharmaceuticals Co., Ltd. holds 333.85M in cash and equivalents against 15.07M in total debt, resulting in a net debt position of -33.95M. Total book value stands at 486.08M, with working capital of 321.86M providing operational flexibility.

Andros Pharmaceuticals Co., Ltd.'s most recent stock split took place on September 25, 2025 with a 901:931 split ratio.